Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pharma Industry Strives to Strengthen Ties with DPJ
March 1, 2010
- Abbott Completes Acquisition of Solvay Pharmaceuticals
March 1, 2010
- Nihon Medi-Physics Initiates PI Trial for NMK36
March 1, 2010
- Prospects of Incretin-Related Drugs in Japan: 2(1)
March 1, 2010
- NIMS Develops DES for Vascular Endothelial Formation
March 1, 2010
- Prospects of Incretin-Related Drugs in Japan: 2(2)
March 1, 2010
- CMIC to Support Korean Hospitals in Developing Medical Devices
March 1, 2010
- Korosho Completes Hearings of Makers
March 1, 2010
- Teva-Kowa, Taisho Pharm to Integrate Marketing Divisions
March 1, 2010
- Korosho Compiles SOP for Revising Package Inserts
March 1, 2010
- New Method Proposed to Show Equivalence of Generics and Original Drugs
March 1, 2010
- CDFS Recommends Approval for Vectibix from Takeda
March 1, 2010
- Eliminate Distinction between Clinical Research and Trials, Introduce IND System: Prof. Kawakami
March 1, 2010
- Shionogi Applies for Rapiacta for Pediatric Use
March 1, 2010
- Consider Ethnic Diversity at Early Stage of Drug Development: Dr Iwasaki
March 1, 2010
- Olmetec Approved for Children, Adolescents Aged 6-16
March 1, 2010
- Takeda Begins PIII Program for Hematide in Japan
March 1, 2010
- Kissei Returns Marketing Right for Cinalong to UCB
March 1, 2010
- Toyama Chemical Initiates PII Trial for T-705 in the US
March 1, 2010
- Maruho to Market Actosin from April
March 1, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…